Bioidentical hormones are versions of estradiol, progesterone, and testosterone that share the exact molecular structure of the hormones the human body produces. The term has become a major search topic — roughly 20,000 monthly U.S. searches — partly because of celebrity endorsements and partly because patients are looking for clearer alternatives to older synthetic HRT formulations. This guide breaks down what "bioidentical" actually means, where FDA-approved bioidentical products differ from custom-compounded versions, what current society guidelines say about safety, and how the modern telehealth landscape prescribes them.
Key facts at a glance
- "Bioidentical" describes molecular structure, not regulatory status — both FDA-approved and unregulated compounded products use the label.
- FDA-approved bioidentical estradiol and micronized progesterone have robust safety data; compounded bioidentical hormone therapy (cBHT) does not.
- The 2020 NASEM report and 2022 NAMS Position Statement both recommend FDA-approved options over compounded ones when bioidenticals are clinically appropriate.
- Typical out-of-pocket cost is $20-$60/month for generic FDA-approved formulations versus $75-$200/month for compounded pellets, creams, or troches.
What "bioidentical hormones" actually means
In clinical pharmacology, a bioidentical hormone has the same chemical structure as the corresponding endogenous human hormone. The three most commonly discussed are 17β-estradiol, progesterone (specifically micronized progesterone), and testosterone. The term itself is not defined by the FDA — it emerged in marketing literature in the 1990s and has since been adopted by both regulated drug manufacturers and compounding pharmacies¹.
This creates a critical distinction. A 0.05 mg estradiol transdermal patch — an FDA-approved product manufactured to USP standards — is bioidentical. A pharmacist-mixed estradiol/estriol cream prepared individually for one patient is also marketed as bioidentical, but it has not been evaluated by the FDA for safety, efficacy, or dose consistency². The molecular target is the same; the regulatory journey is not.
According to the 2015 Endocrine Society Clinical Practice Guideline, an estimated 1-2.5 million U.S. women use compounded bioidentical hormone therapy annually, often under the assumption that "bioidentical" implies "natural" or "safer"³. Current evidence does not support that assumption.
FDA-approved versus compounded bioidentical hormone therapy
The distinction between regulated and compounded products is the single most important concept in this category, because the safety evidence is asymmetric.
FDA-approved bioidentical products
FDA-approved bioidentical hormones include transdermal 17β-estradiol patches (typical doses 0.025-0.1 mg/day), estradiol gels and sprays, vaginal estradiol tablets and rings, and oral micronized progesterone (typically 100-200 mg/night). These products have undergone Phase III trials, carry FDA-approved labeling, and are produced under Good Manufacturing Practice standards⁴.
The 2022 NAMS Hormone Therapy Position Statement endorses these formulations as appropriate first-line options for symptomatic menopausal women under 60 or within 10 years of menopause onset, provided no contraindications exist¹. Transdermal estradiol in particular shows a lower venous thromboembolism risk profile than oral conjugated estrogens in observational data⁷.
Compounded bioidentical hormone therapy (cBHT)
cBHT covers pharmacist-mixed creams, troches, pellets, and combination products often containing estradiol, estriol, estrone, progesterone, testosterone, and sometimes DHEA. These are typically prescribed based on saliva or serum "hormone level testing" — a practice that the Endocrine Society and NAMS both note has poor reproducibility and does not reliably predict symptom response³.
The 2020 National Academies of Sciences, Engineering, and Medicine (NASEM) report on cBHT was unusually blunt: it concluded that there is insufficient evidence to support the broad use of compounded bioidentical hormones, raised concerns about dose inconsistency (some compounded pellets delivered supraphysiologic testosterone levels), and recommended restricting compounding to documented medical need such as documented allergy to an FDA-approved excipient². ACOG reaffirmed in 2020 that compounded bioidenticals should not be presented as safer or more effective than FDA-approved alternatives⁵.
Forms, dosing, and treatment approaches
Bioidentical hormone therapy is delivered through multiple routes, and route matters as much as molecule.
Common FDA-approved approaches discussed in current society guidelines include:
- Transdermal estradiol patches (0.025-0.1 mg/day), changed once or twice weekly, often paired with oral micronized progesterone 100 mg nightly for women with an intact uterus.
- Estradiol gel or spray for women preferring daily application; absorption variability is well-documented in the labeling⁶.
- Low-dose vaginal estradiol (10 mcg tablets or 7.5 mcg/day rings) for genitourinary syndrome of menopause without significant systemic absorption.
- Oral estradiol for patients without elevated VTE or cardiovascular risk.
Compounded approaches frequently include subcutaneous testosterone or estradiol pellets (inserted every 3-6 months), bi-est and tri-est creams (typically 80/20 estriol/estradiol or 10/10/80 estrone/estradiol/estriol), and oral troches. Pellets in particular have been associated with persistent supraphysiologic hormone levels in case series, which is one reason the Endocrine Society does not recommend them⁸.
None of this is a personal recommendation. Choice of formulation, dose, and duration is an individualized clinical decision and should be made with a clinician familiar with menopause guidelines — ideally a NAMS-Certified Menopause Practitioner.
Telehealth provider options for bioidentical hormone prescribing
Several telehealth platforms specialize in menopause care and prescribe FDA-approved bioidentical hormones. They differ meaningfully in insurance acceptance, clinician credentials, and formulary scope.
Midi Health accepts most major commercial insurance plans and Medicare in many states; its clinical team includes NAMS-Certified Menopause Practitioners and prescribes FDA-approved estradiol patches, gels, and oral micronized progesterone. Winona operates as a cash-pay async-first model focused on bioidentical estradiol and progesterone, with pricing typically bundled into a monthly subscription. Alloy Women's Health is cash-pay and run by a clinical team of menopause specialists; its formulary emphasizes FDA-approved bioidentical options including transdermal estradiol and oral micronized progesterone. Gennev accepts some commercial insurance and pairs OB/GYN consultations with optional registered dietitian support.
Compounded bioidentical hormone therapy is less commonly offered through these mainstream menopause telehealth brands; patients seeking cBHT typically work with local compounding-pharmacy-affiliated clinics. Some brand mentions on this page link to our editorial reviews.
Safety, contraindications, and when to talk to a clinician
Bioidentical hormone therapy — whether FDA-approved or compounded — carries the same general contraindications as conventional menopausal HRT. According to NAMS and ACOG, absolute contraindications include known or suspected estrogen-sensitive breast cancer, unexplained vaginal bleeding, active or recent venous thromboembolism, active liver disease, and recent stroke or myocardial infarction¹⁵.
Specific to compounded products, NASEM identified additional safety concerns: dose-to-dose variability has been documented to exceed ±20% in some compounding analyses, sterility of injectable and pellet preparations is not consistently verified, and adverse-event reporting is not centralized in the way FDA MedWatch handles approved products². For pellets specifically, removal of an over-dosed pellet requires minor surgical extraction.
Red flags warranting clinician attention include new breast lumps, unexplained vaginal bleeding after starting therapy, calf swelling or chest pain suggestive of thrombosis, severe headache or visual changes, and persistent abdominal pain. Routine follow-up — typically at 3 months after initiation and annually thereafter — is standard practice in NAMS-aligned care¹.
This article does not constitute medical advice. Anyone considering bioidentical hormone therapy should discuss benefits, risks, and personal contraindications with a qualified clinician.
Cost and insurance considerations
Cost varies substantially by formulation and regulatory status.
FDA-approved generic estradiol patches typically run $20-$45/month with commercial insurance copays and $30-$60/month cash-pay using GoodRx-style discount programs. Oral micronized progesterone 100 mg generic runs roughly $15-$35/month. Brand-name FDA-approved combinations (e.g., estradiol/norethindrone) can range from $80-$200/month depending on coverage⁶.
Compounded bioidentical formulations are nearly always cash-pay. Typical price ranges reported by compounding pharmacies and telehealth clinics include $75-$150/month for bi-est or tri-est creams, $40-$90/month for oral troches, and $300-$600 per pellet insertion procedure repeated every 3-6 months (effectively $50-$200/month amortized). Initial telehealth consultation fees range from $0 (insurance-billed) to $250 (cash-pay specialty clinics).
A 2020 analysis cited in the NASEM report noted that out-of-pocket spending on compounded bioidenticals in the U.S. exceeded $1.3 billion annually, despite the lack of comparative effectiveness data². Insurance coverage of FDA-approved bioidentical options is one of the strongest economic arguments for the regulated category.
Frequently asked questions
Are bioidentical hormones safer than synthetic HRT? Evidence does not support broad claims that bioidentical hormones are safer than conventional HRT. FDA-approved bioidentical estradiol and micronized progesterone have safety data; custom-compounded versions do not. The 2022 NAMS Position Statement recommends FDA-approved options when bioidenticals are clinically appropriate.
What's the difference between bioidentical and synthetic hormones? Bioidentical hormones (estradiol, progesterone, testosterone) match the molecular structure of hormones the body produces. Synthetic hormones like conjugated equine estrogens or medroxyprogesterone acetate differ structurally. Both categories include FDA-approved products.
Does insurance cover bioidentical hormones? Most commercial plans cover FDA-approved bioidentical products such as estradiol patches, gels, and oral micronized progesterone. Custom-compounded bioidentical hormone therapy (pellets, creams) is typically not covered and is paid out-of-pocket.
Are bioidentical hormone pellets FDA-approved? No. Hormone pellets are compounded products and have not been evaluated by the FDA for safety or efficacy. NAMS and the Endocrine Society have raised concerns about supraphysiologic dosing and lack of long-term data.
How long can someone take bioidentical hormones? Duration is individualized. The 2022 NAMS Position Statement supports continuing menopausal hormone therapy as long as benefits outweigh risks, reassessed annually with a clinician. There is no arbitrary stopping point at age 65.
Can bioidentical hormones be prescribed via telehealth? Yes. Telehealth clinics including Midi Health, Winona, Alloy, and Gennev prescribe FDA-approved bioidentical estradiol and progesterone after a clinical intake. Compounded formulations are less commonly offered through major telehealth menopause platforms.
Sources
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35797481/
- National Academies of Sciences, Engineering, and Medicine. The Clinical Utility of Compounded Bioidentical Hormone Therapy. 2020. https://nap.nationalacademies.org/catalog/25791/the-clinical-utility-of-compounded-bioidentical-hormone-therapy-a-review
- Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. https://pubmed.ncbi.nlm.nih.gov/26444994/
- Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy. Mayo Clin Proc. 2011;86(7):673-680. https://pubmed.ncbi.nlm.nih.gov/21531972/
- ACOG Committee Opinion No. 532: Compounded bioidentical menopausal hormone therapy. Obstet Gynecol. 2012;120(2 Pt 1):411-415 (reaffirmed 2020). https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2012/08/compounded-bioidentical-menopausal-hormone-therapy
- U.S. Food and Drug Administration. Menopause & Hormones: Common Questions. https://www.fda.gov/consumers/free-publications-women/menopause-and-hormones-common-questions
- Pinkerton JV. Hormone Therapy for Postmenopausal Women. N Engl J Med. 2020;382(5):446-455. https://pubmed.ncbi.nlm.nih.gov/32023375/
- Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. https://pubmed.ncbi.nlm.nih.gov/31498871/
Related brands & guides
- Midi Health review — insurance-friendly menopause telehealth with NAMS-certified clinicians
- Winona review — cash-pay async bioidentical HRT subscription
- Alloy Women's Health review — menopause-specialist cash-pay clinic
- Gennev review — OB/GYN + dietitian model, some insurance accepted
Updated May 29, 2026. Reviewed by Dr. Maya Chen, MD, NAMS-CMP.